Cefmenoxime

Summary

Cefmenoxime (CHEMBL1201224) is an approved small-molecule antibacterial drug (ATC S02AA18); indicated across 2 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S02AA18 (+2 more)
• Indications: 2 conditions
• Chemistry: 511.6 Da · C16H17N9O5S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201224
Name	Cefmenoxime
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9570757
ChEBI	CHEBI:55490
ATC	S02AA18, J01DD05, S01AA31
Molecular formula	C16H17N9O5S3
Molecular weight	511.6
InChIKey	HJJDBAOLQAWBMH-YCRCPZNHSA-N

SMILES: CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)O

IUPAC name: (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A third-generation cephalosporin antibiotic, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7β-position and a [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl group at the 3-position.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefmenoxima, Cefmenoxime, SCE-1365, CEFMENOXIME, cefmenoxime

Parent form; salt/anhydrous children: CHEMBL3183193

Patent coverage: 1,767 distinct patent families (5,981 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Progesterone receptor, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR1I2	6.15	AC50	710	nM	CHEMBL_ACT_25188345
PGR	5.75	AC50	1800	nM	CHEMBL_ACT_25222307
NR1I2	5.47	AC50	3400	nM	CHEMBL_ACT_25223896

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).